摘要
Abstract
Objective:To investigate the diagnostic value of serum oncostatin M(OSM)alone and in combination with anti-Saccharomyces cerevisiae antibody(ASCA),perinuclear anti-neutrophil cytoplasmic antibody(pANCA),and interleukin-6(IL-6)in inflammatory bowel disease(IBD).Methods:A cross-sectional study design was adopted.One hundred consecutive IBD patients admitted to Huizhou First Hospital between February and November 2024 were enrolled,including 75 with Crohn's disease(56 males,19 females;mean age of 30±11 years)and 25 with ulcerative colitis(18 males,7 females;mean age of 34±11 years).One hundred healthy individuals undergoing physical examinations were selected as the control group(74 males,26 females;mean age of 33±11 years).Serum levels of OSM,ASCA(IgG/IgA),pANCA(IgG),and IL-6 were measured using enzyme-linked immunosorbent assay.A logistic regression model was established for combined diagnosis,and the diagnostic performance of individual and combined markers was evaluated using receiver operating characteristic(ROC)curve analysis.Results:The area under the ROC curve(AUC)for serum OSM alone in diagnosing IBD was 0.900(95%CI:0.858-0.942).At the optimal cut-off value of 64.92 pg/mL,the sensitivity was 85%and specificity 87%.Among combined models,the five-marker panel(ASCA IgG+OSM+IL-6+ASCA IgA+pANCA IgG)demonstrated the highest diagnostic efficacy,with an AUC of 0.984(95%CI:0.969-0.999),sensitivity of 93%,and specificity of 96%.Conclusion:Serum OSM exhibits good diagnostic value for IBD.Combining OSM with ASCA,pANCA,and IL-6 significantly improves diagnostic accuracy,suggesting that a multi-marker strategy holds promising clinical potential for IBD diagnosis.关键词
炎症性肠病/克罗恩病/溃疡性结肠炎/抑瘤素M/血清学标志物Key words
inflammatory bowel disease/Crohn's disease/ulcerative colitis/oncostatin M/serological markers分类
医药卫生
